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As the recipient of the 2011 SC Governor's Award for Excellence in Scientific Research, I've been 
asked to describe my research and some of the accomplishments of my laboratory while at the 
University of South Carolina. My research is focused on understanding the structure and function 
of the pore-forming proteins of the human"complement system", and in particular complement 
protein "C8". The complement system is a group of blood proteins that have a key role in immune 
defense. Much of what is known today about the structure and function of human C8 can be 
attributed to work performed over many years by my graduate students and postdoctoral fellows. 
Introduction -  
 The human "complement system" is composed of 
approximately 35 different proteins, enzymes, receptors and 
regulatory molecules found primarily in blood. The system is 
referred to as complement because it "complements" or 
enhances the ability of the immune system to defend against 
pathogens, e.g. bacteria, viruses, etc. The system is 
"activated" either by the interaction of complement proteins 
with antibody-antigen complexes (classical pathway) or by 
interaction with the unusual carbohydrate found on the surface 
of pathogenic (non-self) organisms (lectin and alternative 
pathways).  Each activation pathway leads to the "terminal 
pathway" and formation of the end-product of complement 
activation. This end-product is the "membrane attack 
complex" of complement or "MAC", a large (~106 kDa) 
complex composed of complement proteins C5b, C6, C7, C8 
and multiple copies of C9 (1-4). The MAC kills bacteria by 
forming a pore or "hole" in the bacterial cell membrane. 
 The sequence of interactions leading to MAC formation is 
well defined; however, the mechanism by which the MAC 
disrupts membrane organization is poorly understood. MAC 
assembly begins with local production of C5b by activated 
complement (Fig. 1). This is followed by binding of C6 to 
form a soluble, noncovalently-linked C5b-6 complex. 
Subsequent binding of C7 produces an amphiphilic complex 
(C5b-7) that has an affinity for cell membranes. C5b-7 binds 
to the outer portion of membrane bilayers and only minimally 
penetrates the interior. Once on the membrane, C5b-7 binds 
C8 and forms a tetrameric C5b-8 complex. The ultrastructure 
of C5b-8 has no pore-like features; however, this complex 
causes leakage of synthetic lipid vesicles, increases ion-
conductance in planar lipid bilayers, and promotes the slow 
osmotic lysis of simple cells such as heterologous 
erythrocytes. Photolabeling studies using membrane-restricted 
probes identified the C8α subunit as the major C5b-8 
component inserted in the membrane (5). In the final step of 
MAC formation, C5b-8 binds and initiates the self-
polymerization of C9 to form a cylindrical transmembrane 
pore composed of 12-18 C9 molecules (poly C9) (3,6). On 
bacteria, the MAC increases outer membrane permeability, 
which in turn induces lethal changes in the inner membrane. 
Other than proteolytic cleavage of C5, all steps leading to 
MAC formation are nonenzymatic and the protein interactions 
are all noncovalent. 
 Individually, the five MAC components circulate in blood 
as hydrophilic proteins, but when combined they form an 
amphiphilic complex capable of intercalating into cell 
membranes. The MAC does not degrade membrane lipid but 
instead produces a disruptive rearrangement that causes 
osmotic lysis of simple cells such as erythrocytes, initiates 
intracellular signaling events in nucleated cells, and disrupts 
the outer membrane of bacteria. Our own cells contain CD59, 
a membrane-anchored protein that protects us from 
complement-mediated damage by preventing assembly of a 
functional MAC. 
 The MAC components interact in a highly specific and 
sequential manner once C5b is formed. As each intermediate 
complex is formed, binding specificity changes and is directed 
towards the next component incorporated. Once associated, 
the affinity between components is high despite the 
noncovalent nature of their interactions. Dissociation can only 
be accomplished by solubilization of the membrane and 
denaturation of the MAC. The goal of our program has been 
to identify structural features that specify the order in which 
these proteins bind, and the mechanism by which they 
undergo a hydrophilic to amphiphilic transition that enables 
them to bind to lipid. Our strategy has been to focus on 
identifying structure-function relationships in one component, 
namely human C8, and thereby gain insight into how the other 
MAC components function. Understanding how the MAC is 
assembled and its function may lead to the development of 
therapeutic pore-forming analogues that could be used to 
attack undesirable human cells, e.g. cancer cells.  
The MAC Family Proteins  
 Human C5b contains two disulfide-linked subunits and is 
the largest MAC protein (180 kDa). C6, C7 and C9 are single 
chain proteins of approximately 105 kDa, 92 kDa and 72 kDa, 
respectively. C8 (151 kDa) is the most complex in that it is 
composed of three nonidentical, genetically distinct subunits 
(α = 64 kDa; β = 64 kDa and γ = 22 kDa) (7). These subunits 
are arranged as a disulfide-linked C8α-γ heterodimer that is 
noncovalently associated with C8β. The affinity between C8α-
γ and C8β is high. Dissociation can only be achieved using 
denaturing agents or high ionic strength buffers. 
 Our discovery in the 1980's that each C8 subunit was
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Fig. 1 Assembly of the Membrane Attack Complex (MAC). The components and sequence of interactions are described in the text. The inset 
shows an EM of a typical membrane pore formed by poly C9 within the MAC. 
 
encoded in a different gene was significant because C8 was 
thought to be a single gene product, i.e. synthesized as a 
single-chain precursor that was posttranslationally cleaved. 
This discovery came as we were characterizing human liver 
cDNA clones to determine the amino acid sequence of C8 (8). 
The results established that C8 was composed of three 
different proteins rather than one. Our efforts to determine the 
sequences and genomic organization of C8 together with the 
work of others provided the first evidence of a structural and 
evolutionary relationship between the MAC proteins. 
 Human C6, C7, C8α, C8β, and C9 are homologous and 
together form the "MAC family" of proteins. Family members 
exhibit sequence similarity and have a highly conserved 
modular organization (Fig. 2) (4,9). Their genomic structures 
are also similar with respect to exon length and boundaries. A 
distinctive feature of each is the presence of cysteine-rich N- 
and C-terminal  modules that are ~40–80 amino acids in 
length. The modules exhibit sequence similarity to those 
found in a variety of proteins unrelated to complement. 
Although not considered a module, the central portion of each 
protein (~ 40 kDa) is designated MACPF to emphasize its 
conservation among the MAC proteins and its sequence 
similarity to perforin, a 70 kDa pore-forming protein released 
from secretory granules of cytotoxic T lymphocytes. 
 The conserved organization of the MAC proteins initially 
suggested the modules themselves may mediate protein-
protein interactions during MAC assembly. This was 
consistent with the view that the MAC can be thought of as a 
"heteropolymer" formed from structurally similar but distinct 
monomeric units. Also noteworthy was the fact these modules 
mediate protein-protein interactions in other systems. MAC 
assembly requires binding interactions that are highly ordered 
and the question of whether specificity is determined by 
differences in fine-structure of the modules or sequence 
variations within the MACPF domains was important to 
answer.   
Properties of Human C8 
 Our focus on C8 has provided valuable insight into the 
specificity of interactions between the MAC components and 
their ability to undergo a hydrophilic to amphiphilic 
transition.  Unlike the other MAC proteins, C8 occurs in 
blood as a complex of C8α-γ and C8β. Our abilityto purify C8 
in large quantities from blood, dissociate C8α-γ from C8β, 
and separate C8α from C8γ has allowed the assignment of 
individual roles for these subunits in MAC formation and 
function. Results indicate each subunit performs multiple 
binding functions. Extending these findings to the next level 
of detail, i.e. localizing the binding regions in each subunit, 
has been particularly challenging. The large size and number 
of disulfide linkages within C8α and C8β has limited our 
ability to produce and manipulate these proteins using 
recombinant DNA technology, i.e. bacterial or eukaryotic 
expression systems. Nevertheless, we succeeded in narrowing 
the location of sites in each subunit that are involved in 
several key binding interactions.  
Binding Sites on C8α 
 C8α contains several binding sites (Fig. 3). One mediates 
interaction between C8α-γ and C8β to form C8. C8α also has 
a site that recognizes C8γ and facilitates the biosynthetic 
assembly of C8α-γ. Within C5b-8, C8α functions to bind and 
direct C9 into the MAC. C8α is also recognized by CD59, a 
complement regulatory protein that protects human cells by 
binding C8α and C9 and inhibiting formation of the MAC.  
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Fig. 2 The MAC Family Proteins. Modules and other structural features of each protein are described in the inset. All cysteines form intrachain 
disulfide bonds except C164 in C8α that is linked to C40 in C8γ. Residue numbers identify module boundaries. 
 
Fig. 3 Location of Binding sites on C8α and C8β. Residue numbers 
identify segments containing binding sites for the indicated proteins. 
 
C8α also contributes to the cytolytic activity of the MAC by 
interacting directly with membrane lipid. These interactions 
occur simultaneously during MAC formation; therefore they 
were assumed to involve physically distinct, nonoverlapping 
sites. The following summarizes our progress towards 
assigning these binding functions to specific regions of C8α.     
C8β Binding Site 
 Binding between C8α and C8β was initially observed using 
C8α that was purified after cleavage of the interchain 
disulfide in C8α-γ (10). C8α bound C8β to form a 1:1 
complex in solution. Subsequent studies used recombinant 
full-length C8α produced in baculovirus to demonstrate 
noncovalent binding to C8β in the absence of C8γ (11). 
Together, these results suggested that binding of C8α-γ to C8β 
is mediated strictly by C8α.   
 This was confirmed when the C8α MACPF domain was 
shown to contain the binding site for C8β. The MACPF 
segment of C8α (αMACPF) was coexpressed with C8γ in 
COS cells and formed a disulfide-linked αMACPF-γ dimer 
(12). Assays showed the secreted dimer had the ability to bind 
C8β. Subsequently, we succeeded in producing the C8α 
MACPF domain alone in large quantities in E.coli and showed 
that it also can bind C8β with high affinity (13). This 
established unequivocally that the principal binding site for 
C8β lies within the C8α MACPF domain. 
C8γ Binding Site  
 Although C8α occurs as a disulfide-linked heterodimer with 
C8γ, it retains the ability to interact noncovalently with C8γ 
after cleavage of the interchain disulfide bond. Such binding 
has also been observed with recombinant forms of C8α and 
C8γ in which the linking Cys residues have been deleted (12). 
These observations and the fact that biosynthetic processing in 
the liver hepatocyte requires noncovalent association prior to 
disulfide bond formation indicates C8α and C8γ contain 
mutually recognizable binding sites.   
 The location of the C8γ binding site within the MACPF of 
C8α was suggested from a comparative analysis of MACPF 
sequences in C6, C7, C8α, C8β, and C9. The C8α MACPF 
sequence is distinctive in that it contains a unique indel 
(insertion/deletion) between residues 159-175, which includes 
C164 that forms the disulfide bond to C40 in C8γ. Indels in 
 
 Journal of the South Carolina Academy of Science, [2012], 10(1) 4 
  
homologous proteins frequently correspond to loops and are 
often regions of functional significance; therefore this 
segment of C8α was considered a possible C8γ binding site. 
The indel was examined for its ability to mediate binding of 
C8γ by using a chimeric form of C8β as a substitute for C8α 
(14). Insertion of the C8α indel sequence into C8β and 
coexpression of this chimera with C8γ in COS cells produced 
an atypical disulfide-linked C8β-γ dimer. These results 
unequivocally established that intracellular binding of C8γ to 
C8α is mediated solely by residues within the C8α indel. 
C9 Binding Site  
 One function of C8 is to mediate incorporation of the first 
C9 into the MAC. C9 has little affinity for C5b-6 or C5b-7 but 
readily binds to C5b-8. Such binding induces an apparent 
conformational change in the first C9 that initiates self-
polymerization and formation of poly C9. Studies using 
purified C8 and C9 have shown that these proteins can form a 
1:1 complex in solution (15,16). 
 Binding between C8 and C9 is mediated principally by 
C8α. Interaction between C9 and C8α-γ or C8α can be 
demonstrated over a range of ionic strengths whereas binding 
to C8β or C8γ is negligible. C8α when combined with C8β 
exhibits both hemolytic and bactericidal activity in the 
presence of C9 (11,17). Thus, C8α is the key component for 
binding and incorporation of C9 into the MAC. 
 In an effort to locate the C9 binding site on C8α, truncated 
and chimeric C8α in which modules were deleted or 
exchanged for those in C8β were expressed independently or 
as heterodimers with C8γ and combined with C8β. Initial 
studies used COS cells for low level expression and then later 
used E. coli to express larger quantities of αMACPF or 
αMACPF-γ for purification and characterization (13). These 
were tested for their ability to bind C9 in solution and express 
hemolytic activity. Collectively, the results showed that 
binding between C8 and C9 is dependent on a site located 
within the C8α MACPF domain. 
CD59 Binding Site  
 MAC formation is regulated in part by the binding of CD59 
to C8. Human CD59 is a 20-kDa membrane-bound 
complement regulatory protein that protects human blood and 
vascular cells from damage by complement. Analysis of the 
physical association of CD59 with components of the MAC 
indicated C8α contains a binding site for CD59 (18). A series 
of studies using recombinant human-rabbit C8 chimeric 
proteins eatablished that CD59 binds to a conformationally 
sensitive site on C8α that is centered on residues 334-385 
(19). This binding interferes with the normal assembly of the 
MAC and thereby protects our own cells from random MAC 
formation and damage. 
Lipid Binding Site  
 C8α contains one or more lipid binding sites that become 
exposed within the MAC. Evidence for this comes from 
photolabeling studies using membrane-restricted probes to 
identify components of the MAC that are inserted into the 
bilayer (5). In both C5b-8 and the MAC, extensive labeling of 
C8α suggests it is inserted into the lipid bilayer, and that it 
contributes significantly to membrane perturbation. In the 
MAC, C9 is also heavily labeled, consistent with its role in 
forming poly C9 and the pore-like structure of the MAC. 
Binding Sites on C8β 
 C8β also contains several binding sites (Fig. 3). One site 
mediates binding to C8α in C8α-γ. A second site mediates 
incorporation of C8 into the MAC. C8β alone has a high 
affinity for C5b-7 and carries the structural epitope(s) 
recognized by this complex. Because C8β can simultaneously 
interact with C8α-γ and C5b-7, the respective binding sites 
must be physically distinct. Within the MAC, C8β also has the 
capacity to associate with lipid. Photolabeling experiments 
indicate C8β is in contact with the bilayer, although to a lesser 
extent than C8α or C9.     
C8α Binding Site  
 To localize the C8α binding region, C8β constructs were 
prepared in which the N- and/or C-terminal modules were 
deleted or exchanged with the corresponding modules in C8α.  
These were expressed recombinantly and the products tested 
for binding to C8α-γ. Results initially suggested a role for the 
N-terminal T1 module and MACPF domain but later studies 
using recombinant C8β MACPF expressed in E. coli revealed 
that the binding site for C8α resides entirely within the C8β 
MACPF domain (20,21). 
C5b-7 Binding Site 
 Binding of C8 to C5b-7 is essentially irreversible; 
dissociation can only be accomplished by denaturing the 
resulting C5b-8 complex. Binding studies using purified C8 
subunits revealed that C8β and C8 have a comparable affinity 
for C5b-7 (22). Furthermore, C8β effectively blocks C8 
incorporation into the MAC; therefore it must compete for the 
same binding site on C5b-7. To identify the portion of C8β 
recognized by C5b-7, truncated recombinant C8β constructs 
were combined with C8α-γ and assayed for their ability to 
associate with C5b-7 and express C8 hemolytic activity (20). 
Assays were limited to constructs that bind C8α-γ because 
C8α is required for C9 binding. Constructs that contained only 
the C8β MACPF domain when combined with C8α-γ were 
found to be hemolytically active, thus confirming that the 
C5b-7 binding site in C8β lies within its MACPF domain (21). 
Properties and Structure of C8γ  
 Although its structure is well characterized, the function of 
C8γ in the complement system remains elusive. Over the 
years, several possibilities have been considered but 
subsequently discounted by studies performed in our 
laboratory (reviewed in ref 23). C8γ is not required for the 
synthesis and secretion of C8α; C8α can be expressed 
independently as a recombinant protein in mammalian and 
insect cells. Binding between C8α-γ and C8β is likewise not 
dependent on C8γ; purified C8α and C8β can form a 1:1 
complex in the absence of C8γ. C8γ is also not essential for 
incorporation of C8 into the MAC nor is it required for MAC 
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cytolytic activity. Although not as efficient, a complex of C8α 
+ C8β is an effective substitute for C8 in the MAC-mediated 
lysis of simple cells such as erythrocytes and in the killing of 
gram-negative bacteria (11,17).  
 C8γ is structurally unrelated to any complement protein; it 
is a member of the lipocalin family of proteins that have the 
common ability to bind small hydrophobic ligands, e.g. 
retinol, fatty acids, steroids, pheromones, etc (24-26). 
Lipocalins exhibit little sequence similarity yet have a highly 
conserved fold. The core structure consists of an eight-
stranded antiparallel β-barrel that resembles a calyx or cup-
shaped structure with a binding pocket for a small molecule. 
Residues lining the interior of the calyx and the size of the 
calyx vary among family members, thus lipocalins exhibit 
different ligand specificities.  
 To gain insight into the identity of a putative ligand for 
C8γ, we produced human recombinant C8γ in insect cells and 
solved the crystal structure to 1.2 Å resolution (27). C8γ 
displays a typical lipocalin β-barrel fold with a potential 
ligand binding site. Although it has a similar fold, C8γ differs 
from most lipocalins in that its binding pocket is divided into 
a hydrophillic upper portion and an unusually large, lower 
hydrophobic cavity. Access to the lower cavity is restricted by 
the close proximity of two tyrosine side chains. The entrance 
to the lower cavity is narrow; however it is accessible to a 
ligand if there is movement of the tyrosines. This was shown 
in crystallographic studies using lauric acid as a ligand; 
movement of the tyrosine side chains allowed the alkyl 
portion of laurate to penetrate into the lower cavity (28). The 
features of the binding pocket suggest that any natural ligand 
for C8γ will have a narrow hydrophobic moiety at one end 
and a negatively charged group at the other end. 
 Related studies indicate C8γ may not normally bind a small 
molecule ligand. C8γ was co-crystallized with a 19-residue 
synthetic peptide encoding the C8α indel that binds C8γ (29). 
The crystal structure showed the indel peptide completely 
filling the upper portion of the C8γ ligand binding pocket and 
in contact with all four loops at the calyx entrance. Binding 
studies performed with the peptide in solution suggested the 
C8γ ligand binding site is also blocked by the indel segment 
of C8α within C8. This was later confirmed when structures 
of αMACPF-γ and C8 (see below) showed that access to the 
C8γ ligand binding site would require a major conformational 
change to move the C8α indel away from the calyx entrance. 
αMACPF and the Pore-Forming Bacterial 
Cholesterol Dependent Cytolysins (CDCs) 
 One of the most significant advances in our understanding  
of the MAC came about as a result of our ability to produce 
the ~40 kDa αMACPF domain on a large scale in E. coli. 
Bacteria often do not form the correct disulfide bonds in 
recombinantly expressed proteins. We found that E.coli can 
not only produce a soluble, functional αMACPF domain with 
the correct disulfide bonds but also a disulfide-linked dimer of 
αMACPF and C8γ (αMACPF-γ) when a dual expression 
vector is used to simultaneously express both proteins (13). 
Recombinant αMACPF and αMACPF-γ were purified and 
found to be functional. Our results showed unequivocally that 
the αMACPF domain contains the binding sites for C8β and 
C9. Most importantly, production of αMACPF and αMACPF-
γ on a large scale enabled our laboratory and others to 
crystallize these fragments and obtain the first detailed 
structural information for a human MAC family protein. 
 Insight into how MAC proteins insert into membranes came 
when x-ray crystal structures were simultaneously reported 
for the MACPF-containing protein PluMACPF, and human 
recombinant αMACPF that was generated by our methods 
E.coli (30,31). Importantly, these proteins were found to 
display a fold similar to the pore-forming bacterial CDCs. 
This was subsequently confirmed when we determined the 
crystal structure of αMACPF-γ (32). CDCs are virulent pore-
forming proteins secreted from gram positive bacteria and 
used to invade eukaryotic cells (33). The mechanism of pore 
formation by CDC proteins is well understood. 30-50 CDC 
monomers self-polymerize on cholesterol-rich regions of the 
eukaryotic cell surface to form a circular "pre-pore", which 
upon completion inserts into the membrane as a functional 
pore (34). This process involves a concerted conformational 
change whereby two regions of each CDC monomer, which 
are initially in an α-helical conformation, refold into an 
extended conformation and insert into the bilayer as two 
amphipathic β-hairpins (TMH). TMHs from neighboring 
molecules “share edges” of their β-hairpins to form a 
hydrogen-bonded transmembrane β-barrel. 
 Figure 4 compares the structure of αMACPF-γ to 
intermedilysin (ILY), a well-characterized CDC from 
Streptococcus intermedius (35). Key similarities in the core 
structures include the overall size, the presence of a central β-
sheet, and two α-helical bundles that in ILY refold into 
amphipathic β-hairpins. In the CDCs, refolding of the TMH1 
and TMH2 helical bundles to form β-hairpins is accompanied 
by elongation of the core β-sheet and alignment with a 
neighboring monomer (36,37). The striking structural 
similarity between complement MACPF proteins and the 
CDCs suggests that complement uses a CDC-like mechanism 
for pore formation. 
Structure of Human C8 and a Model of the MAC 
Pore 
 A major milestone was reached in 2011 when we published 
the x-ray crystal structure of whole C8 purified from blood 
(38). This is the first complete structure of a MAC family 
protein and of a protein containing two tightly associated 
MACPF domains. The large size of C8 and its intrinsic 
flexibility made it particularly challenging to crystallize and 
solve the structure, a project that required many years to 
complete. Not surprisingly, C8α-γ and C8β have many of the 
same CDC-like features seen initially in αMACPF-γ. The 
sequence of C9 is 27% and 26% identical to the corresponding 
regions of C8α and C8β, respectively, thus C9 likely has a 
fold similar to these two subunits and the CDCs.  
 The structure of C8 is shown in Fig. 5. The central part of 
the C8α and C8β MACPF domains form large, four-stranded, 
antiparallel β-sheets with a bend and twist in the middle,  
 
 Journal of the South Carolina Academy of Science, [2012], 10(1) 6 
  
Fig. 4 Comparison of the αMACPF-γ and Intermedilysin (ILY) 
Structures. Shown are ribbon models of αMACPF-γ and ILY. The 
core β-sheet is in blue, the two α-helical bundles (TMH1 and TMH2) 
known to re-fold into β-hairpins in ILY and predicted to do so in 
αMACPF are in red. C8γ is green and the cholesterol-binding domain 
in ILY is lavender. Other structural elements are gold. As predicted 
from earlier studies, the entrance to the C8γ β-barrel is occupied by a 
large loop containing the indel segment of αMACPF. 
 
which gives them a “Γ” shape. Their lower part is flanked by 
the TMH α-helical bundles. Together with another helix they 
form the "lower" MACPF subdomain. The upper part of the 
sheet and helices surrounding it forms the “upper” subdomain, 
which makes contacts with the modules, and most likely with 
other MAC proteins. The relative positions of the C8α and 
C8β MACPF subdomains differ as a result of a different bend 
and twist in their central β-sheets. The upper MACPF 
subdomains form very thin, tabular structures tightly packed 
together with the β-sheets facing one another in C8. These 
interactions are likely responsible for the strong binding 
between C8α-γ and C8β. The lower subdomains differ in that 
the sheets are not facing one another but are nearly coplanar; a 
small gap between them shows no edge sharing. Separation of 
the lower subdomains could facilitate refolding of the TMHs 
during insertion into membranes whereas the tightly packed 
upper subdomains are unlikely to change their relative 
position and may have a role in directing and maintaining the 
circular shape of the pore.  
 In CDCs, during transition from pre-pore to pore, the bend 
in the central β-sheet is reduced, the sheet changes from the 
“Γ” shape to a “ ” shape, and the TMHs refold from an α-
helical to an extended conformation, thus elongating the 
central β-sheet and allowing insertion of THMs into the 
membrane. This transition requires a large movement between 
the upper and lower subdomains and is thought to be 
facilitated by four glycines located at the bend of the central 
β-sheets (37). These residues are conserved in C8α and C8β 
and likely have a similar role in refolding of the MACPF 
domains. 
 The oligomeric C8 structure has provided valuable insight 
into how the MAC components interact to form a circular  
Fig. 5 Structure of Human C8. Upper panel is a ribbon model of C8 
showing C8α (red), C8β (blue), and C8γ (green). MACPF domains 
are in dark colors, modules in light. Lower panel shows separate 
views of C8α-γ and C8β oriented as in the upper panel. The central 
MACPF β-sheet is blue, α-helices in TMH1 and TMH2 are red, and 
the remainder of the MACPF domain is gold. The modules are 
located on the periphery of C8 and are lavender. 
 
pore. Athough the structure is of a pair of MACPF proteins in 
a "non-pore" state, the unusual geometrical relationship 
between C8α and C8β has important functional implications. 
Most frequently, homodimeric proteins are related by a 180° 
rotation. By contrast, C8α and C8β are related by a rotation of 
22°, while the translation between their centers is almost 
perpendicular to the rotation axis, resulting in only a small 
(1.6 Å) translational component parallel to the rotation axis. It 
is well established that C8 mediates the binding and 
incorporation of C9 into the MAC, and that this involves a 
specific C9 binding site within the C8α MACPF domain. 
Assuming the modes of binding between C9 and C8α and 
between C9 and C9 are similar to that between C8α and C8β, 
with no translational component, we constructed a model for 
the C8-C9 complex (Fig. 6A). To do this, a homology model 
of C9 was generated based on C8α and rotated (~22°) 
according to the geometrical relationship between C8α and 
C8β. Rotations of the C9 model by multiplicities of 22° 
yielded the positions of  further C9 molecules and resulted in 
a model for the circular MAC pore (Fig. 6B, 6C). The inner 
diameter of the ring is 110 Å, the outer diameter is ~ 220 Å, 
and the height is 90 Å. This agrees well with EM images of 
pores formed by poly C9, which generally have dimensions of 
~ 100 Å and 210 Å for the inner and outer diameters, 
respectively. Also, our pore model contains 16 molecules per 
ring, in excellent agreement with low resolution EM studies of 
pores formed by MAC and poly C9 (3,6). 
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Fig. 6 Model of the MAC Pore. The model assumes that the binding 
mode between C8α and C8β MACPF domains is conserved for C6, 
C7 and C9. (A) View of the modeled C8-C9 complex. Colors 
correspond to C8α (red), C8β (blue), C8γ (green), and C9 (gold). (B) 
Partial model of the MAC. View is of the side facing the membrane. 
Proteins are colored C6 (cyan), C7 (pink), C8α (red), C8β (blue), C8γ 
(green), and C9 (gold). Absent are C5b, the CP and FM modules of 
C6 and C7, and the additional N-terminal T1 module in C6, the 
locations of which could not be predicted. It is assumed the missing 
components do not interfere with circular packing of the MACPF 
domains. (C) The molecular envelope of the model with modules in 
red and MACPF domains in gold. View is of the side facing away 
from the membrane. The modules account for a substantial fraction of 
the exposed surface, which is consistent with their peripheral location 
in C8.  
Conclusion    
 Over the years our research has used the tools of protein 
biochemistry, molecular biology and structural biology to 
study human C8 and obtain information that has significantly 
advanced our understanding of the formation and function of 
the MAC. As a result of our work and related work by others, 
it is now apparent that human complement proteins make 
"holes" in bacterial cells by a mechanism similar to that used 
by bacteria and other lower organisms to make holes in our 
cells. What remains now is to decipher the details of that 
mechanism. This will require a detailed analysis of the 
structure and function of C6, C7 and C9, which will now be 
facilitated by the progress we have made on C8. 
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